Clinical Trials Directory

Trials / Completed

CompletedNCT01281787

PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer

Prevention of Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
320 (actual)
Sponsor
European Institute of Oncology · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to assess whether prophylactic treatment with metoprolol or losartan is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing thoracic surgery for lung cancer, showing elevated plasma levels in NT probrain natriuretic peptide (NT-proBNP), measured in the perioperative period.

Detailed description

Postoperative atrial fibrillation is one of the most common complication after thoracic surgery for lung cancer, with an incidence ranging from 8 to 20% after lobectomy and up to 42% after pneumonectomy. In a recent study we demonstrated that a high perioperative plasma levels of NT-proBNP is able to identify patients at risk for AF (incidence of 65%). It has also been demonstrated that the renin-angiotensin system may play an important role in the pathophysiology of atrial fibrillation and that angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) are able to prevent atrial fibrillation in patients with heart failure, after myocardial infarction, in hypertensive patients and after electrical cardioversion.

Conditions

Interventions

TypeNameDescription
DRUGMetoprololMetoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
DRUGLosartanLosartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay

Timeline

Start date
2008-04-01
Primary completion
2013-06-01
Completion
2013-10-01
First posted
2011-01-24
Last updated
2014-06-18

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01281787. Inclusion in this directory is not an endorsement.